Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Central Nervous System Neoplasms 27 Astrocytoma 15 Oligodendroglioma 14 Glioblastoma 14 Gliosarcoma 12 Glioma 11 Brain Neoplasms 11 Ependymoma 4 Spinal Cord Neoplasms 3 Neuroblastoma 3 Somatostatinoma 2 Neoplasm Metastasis 2 Melanoma 2 Medulloblastoma 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Adenoma, Islet Cell 2 Sarcoma, Ewing 1 Rhabdoid Tumor 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Optic Nerve Glioma 1 Neurotoxicity Syndromes 1 Neuroectodermal Tumors, Primitive 1 Leukemia 1 Insulinoma 1 Glucagonoma 1 Glioma, Subependymal 1 Gastrointestinal Stromal Tumors 1 Gastrinoma 1

Interventions

Gemcitabine 10 Cisplatin 7 S 1 (combination) 6 titanium silicide 2 Oxaliplatin 2 spartalizumab 1 pembrolizumab 1 pamiparib 1 atezolizumab 1 World Health Organization oral rehydration solution 1 Temozolomide 1 Paclitaxel 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Biliary Tract Neoplasms × Temozolomide × Clear all

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡